DUBLIN, April 24, 2017 /PRNewswire/ --
Research and Markets has announced the addition of the "Global Diabetic Therapeutic Market 2017-2021" report to their offering.
The global diabetic therapeutic market to grow at a CAGR of 7.55% during the period 2017-2021.
The report, Global Diabetic Therapeutic Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
The latest trend gaining momentum in the market is focus on oral insulin therapies. Regular insulin treatment is the only cure for type 1 diabetes since the insulin-producing beta cells can no longer produce enough insulin. In type 2 diabetes, insulin is administered when options such as diet, exercise, and oral antidiabetic drugs fail to maintain optimal blood glucose levels. Injections commonly deliver insulin through the subcutaneous tissues.
According to the report, one of the major drivers for this market is change in patient preference. Earlier days, the treatment for diabetes was more popular in hospitals where an endocrinologist or a dietician guided the individuals in type 1 diabetes management. Though there were fruitful results achieved, there were some issues like long waiting times leading to crowding, limited visiting slots, high consultation fees, and non-availability of devices stock have made people to look for alternatives. Due to these reasons, the individuals had to revisit the hospitals repeatedly to get the check-up done. This looked favorable from the view of hospitals as they had high demand.
- Eli Lilly
- Novo Nordisk
Key Topics Covered:
Part 01: Executive summary
Part 02: Scope of the report
Part 03: Market research methodology
Part 04: Introduction
Part 05: Disease overview: Diabetes
Part 06: Pipeline portfolio
Part 07: Market landscape
Part 08: Overview of marketed products
Part 09: Market segmentation by type of disease
Part 10: Market segmentation by drug class
Part 11: Geographical segmentation
Part 12: Market drivers4
Part 13: Impact of drivers
Part 14: Market challenges
Part 15: Impact of drivers and challenges
Part 16: Market trends
Part 17: Vendor landscape
Part 18: Key vendor analysis
Part 19: Appendix
For more information about this report visit http://www.researchandmarkets.com/research/ml3xd5/global_diabetic
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets